These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31981687)

  • 41. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
    Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y
    Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative hepatic toxicity of isoniazid, rifampicin and ethambutol].
    Skakun NP; Tabachuk OE
    Probl Tuberk; 1991; (10):77-9. PubMed ID: 1788241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of repeated administration of rifampicin and isoniazid on vitamin D metabolism in mice.
    Sheng L; Xue Y; He X; Zhu Y; Li H; Wu Y; Dang R; Tang M; Jiang P
    Steroids; 2015 Dec; 104():203-7. PubMed ID: 26476181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
    Chan CH; Or KK; Cheung W; Woo J
    J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro toxic action potential of anti tuberculosis drugs and their combinations.
    Fatima R; Ashraf M; Ejaz S; Rasheed MA; Altaf I; Afzal M; Batool Z; Saleem U; Anwar K
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):501-513. PubMed ID: 23806997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
    TB:HIV Study writing Group
    AIDS; 2017 Jan; 31(3):375-384. PubMed ID: 28081036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The management of tuberculosis: epidemiology, resistance and monitoring.
    Bang D
    Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular genetics of drug resistance in Mycobacterium tuberculosis.
    Zhang Y; Young D
    J Antimicrob Chemother; 1994 Sep; 34(3):313-9. PubMed ID: 7829406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
    Girling DJ
    Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hesperidin Alleviates Oxidative Stress and Upregulates the Multidrug Resistance Protein 2 in Isoniazid and Rifampicin-Induced Liver Injury in Rats.
    Zhang G; Zhu J; Zhou Y; Wei Y; Xi L; Qin H; Rao Z; Han M; Ma Y; Wu X
    J Biochem Mol Toxicol; 2016 Jul; 30(7):342-9. PubMed ID: 27017938
    [No Abstract]   [Full Text] [Related]  

  • 58. Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone.
    Mariappan TT; Jindal KC; Singh S
    J Pharm Biomed Anal; 2004 Nov; 36(4):905-8. PubMed ID: 15533688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-drug resistant tuberculosis burden and risk factors: an update.
    Marahatta SB
    Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.